囊性纤维化与非囊性纤维化患者洋葱伯克霍尔德菌复合群药敏试验方法评估
该研究评估了微量肉汤稀释法、纸片扩散法、琼脂稀释法和梯度扩散法对205株洋葱伯克霍尔德菌复合群(BCC)分离株(100株来自囊性纤维化患者,105株来自非囊性纤维化患者)检测五种抗菌药物的性能。以微量肉汤稀释法为参考,纸片扩散法、琼脂稀释法和梯度扩散法均表现不佳,且培养基制造商和标本来源无显著影响。建议不对BCC分离株常规进行药敏试验,若临床要求则仅采用CLSI参考微量肉汤稀释法并报告MIC值。
要点
- BCC药敏试验中纸片扩散法、琼脂稀释法和梯度扩散法与参考微量肉汤稀释法结果不相关。
- 微量肉汤稀释法对左氧氟沙星、美罗培南、米诺环素和甲氧苄啶-磺胺甲噁唑重复性可接受。
- 不建议对BCC分离株常规开展药敏试验,若需检测仅用CLSI参考微量肉汤稀释法报告MIC。
核心结论
- 纸片扩散法、琼脂稀释法和梯度扩散法(ETEST)与参考微量肉汤稀释法对BCC分离株的药敏结果不相关。
- 推荐不对BCC分离株常规进行药敏试验,若临床医生要求则仅采用CLSI参考微量肉汤稀释法(冷冻保存)并报告MIC值。
研究设计与样本
- 评估参考微量肉汤稀释法、纸片扩散法(使用三个制造商的Mueller-Hinton琼脂)、琼脂稀释法和梯度扩散法对205株BCC分离株的检测性能。
- 分离株包括100株来自囊性纤维化患者和105株来自非囊性纤维化患者,标本来源多样。
- 检测药物为头孢他啶、左氧氟沙星、美罗培南、米诺环素和甲氧苄啶-磺胺甲噁唑。
主要发现
- 全部BCC分离株中,微量肉汤稀释法对头孢他啶、左氧氟沙星、美罗培南、米诺环素和甲氧苄啶-磺胺甲噁唑的重复性分别为93%、98%、99%、98%和96%。
- 以微量肉汤稀释法为参考,纸片扩散法、琼脂稀释法和ETEST均表现不佳。
- Mueller-Hinton琼脂制造商和标本来源均未显著影响方法性能。
关键数值与推荐
- 微量肉汤稀释法重复性:头孢他啶93%,左氧氟沙星98%,美罗培南99%,米诺环素98%,甲氧苄啶-磺胺甲噁唑96%。
- 头孢他啶的微量肉汤稀释法重复性略低于可接受阈值。
临床怎么用
- 临床微生物实验室不应常规对BCC分离株进行药敏试验。
- 若临床医生要求药敏试验,应按照CLSI参考方法进行微量肉汤稀释法(肉汤冷冻保存)并仅报告MIC值。
- 临床医生应知晓BCC药敏试验方法存在显著局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Burkholderia cepacia complex (BCC) is a group of Gram-negative bacteria that cause opportunistic infections, most notably in people with cystic fibrosis (CF), and have been associated with outbreaks caused by contaminated medical products. Antimicrobial susceptibility testing (AST) is often used to guide treatment for BCC infections, perhaps most importantly in people with CF who are being considered for lung transplant. However, recent studies have highlighted problems with AST methods. Here, we address limitations from previous studies to further evaluate BCC AST methods. We assessed the performance of reference broth microdilution (BMD), disk diffusion (DD) using Mueller-Hinton agar (MHA) from three manufacturers, agar dilution (AD), and gradient diffusion (ETEST) for ceftazidime (CAZ), levofloxacin (LVX), meropenem (MEM), minocycline (MIN), and trimethoprim-sulfamethoxazole (TMP-SMX) on a set of 205 BCC isolates. The isolate set included 100 isolates from people with CF and 105 isolates from people without CF from a variety of sources, which enabled us to systematically evaluate whether specimen source impacts AST performance. For all BCC isolates, BMD reproducibility was 93%, 98%, 99%, 98%, and 96% for CAZ, LVX, MEM, MIN, and TMP-SMX, respectively. Using BMD as the comparator method, we show that DD, AD, and ETEST perform poorly, with neither MHA manufacturer nor specimen source significantly impacting method performance. Based on our data, we recommend that routine AST should not be performed for BCC isolates. If a provider requests AST, clinical microbiology laboratories should perform Clinical and Laboratory Standards Institute reference methodology for BMD (stored frozen) and report MIC only.IMPORTANCEAntimicrobial susceptibility testing for the Burkholderia cepacia complex (BCC) is often used to determine eligibility for lung transplant in people with cystic fibrosis. However, problems with method performance have been reported. Here, we systematically evaluate the performance of reference broth microdilution, disk diffusion, agar dilution, and gradient diffusion (ETEST) for BCC organisms isolated from people with and without cystic fibrosis. We show that broth microdilution reproducibility is acceptable for levofloxacin, meropenem, minocycline, and trimethoprim-sulfamethoxazole, while ceftazidime was just below the acceptability cut-off. Regardless of specimen source, the results from disk diffusion, agar dilution, and ETEST do not correlate with broth microdilution. Based on these findings, we recommend that antimicrobial susceptibility testing should not be routinely performed for BCC, and if requested by the provider, only broth microdilution following Clinical and Laboratory Standards Institute guidelines should be used. Providers should be aware of the significant limitations of antimicrobial susceptibility testing methods for BCC.
引用
- Jorth P, Manuel C, McLemore T, et al. Evaluation of antimicrobial susceptibility testing methods for Burkholderia cepacia complex isolates from people with and without cystic fibrosis. J Clin Microbiol. 2025. PMID: 39840992. doi:10.1128/jcm.01480-24
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。